Experiments

Searchable full-text extractions: founding hypothesis, core claims, experimental setups, key results and statistics — pulled out of each paper as structure. Search a cell line, an assay or an entity (e.g. HUH7) and find every paper that worked with it. This corpus stands on its own: most entries carry no reproduction assessment (yet).

• The promoter and the enhancer region of the KLK 3 (prostate specific antigen) gene is frequently mutated in breast tumours and in breast carcinoma cell lines.

  PMID 10188912 · PMC2362704 · British journal of cancer · 1999 · 7 claims · 5 setups

  Full-text index only

  No mutations were found in the protein-coding exons of the PSA gene in breast tumours or cell lines

  breast genomic immunofluorometric receptor pcr

• Comparative proteome analysis of breast cancer and adjacent normal breast tissues in human.

  PMID 17127214 · PMC5054074 · Genomics, proteomics & bioinformatics · 2006 · 8 claims · 7 setups

  Full-text index only

  15 differential protein spots were detected in 11 of 12 (91.7%) breast cancer tissue samples compared with adjacent normal tissue

  breast spots 2d-page stained sds-page 2d-page maldi-tof

• Intrinsic genetic characteristics determine tumor-modifying capacity of fibroblasts: matrix metalloproteinase-3 5A/5A genotype enhances breast cancer cell invasion.

  PMID 17922906 · PMC2242664 · Breast cancer research : BCR · 2007 · 8 claims · 8 setups

  Full-text index only

  Tumor-derived fibroblasts promote higher levels of breast cancer cell invasion than normal fibroblasts

  breast conditioned mda-mb-468 genomic invasion immunofluorescence pcr-rflp

• Surface-enhanced laser desorption/ionization time-of-flight proteomic profiling of breast carcinomas identifies clinicopathologically relevant groups of patients similar to previously defined clusters from cDNA expression.

  PMID 18510725 · PMC2481497 · Breast cancer research : BCR · 2008 · 7 claims · 7 setups

  Full-text index only

  Unsupervised hierarchical clustering of 130 SELDI-TOF peaks yielded six peak clusters and five distinct groups of breast cancer patients.

  lysates breast microarrays imac-preseparated seldi-tof pilot immunohistochemistry

• An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer.

  PMID 18676830 · PMC2680495 · Cancer research · 2008 · 8 claims · 5 setups

  Full-text index only

  PIK3CA mutations are more common in hormone receptor-positive and HER2-positive tumors than in basal-like breast cancers

  breast hormone early-stage mass sanger reverse-phase

• Three assays show differences in binding of wild-type and mutant p53 to unique gene sequences.

  PMID 19925028 · PMC2917581 · Technology in cancer research & treatment · 2009 · 7 claims · 6 setups

  Full-text index only

  Three different DNA binding assays (EMSA, SPA, streptavidin magnetic bead assay) show differences in binding of wild-type and mutant p53 to unique gene sequences

  nuclear wro electrophoretic binding streptavidin

• Liquid chromatography-tandem and MALDI imaging mass spectrometry analyses of RCL2/CS100-fixed, paraffin-embedded tissues: proteomics evaluation of an alternate fixative for biomarker discovery.

  PMID 19856998 · PMC2924679 · Journal of proteome research · 2009 · 7 claims · 4 setups

  Full-text index only

  RCL2/CS100-fixed tissues yield peptide and protein identifications by nanoRPLC-MS/MS comparable to matched fresh-frozen tissues, with proteome coverage not obviously compromised by fixation.

  colonic rcl2 colon nanorplc-ms extraction laser

• Proteomic analysis of RCL2 paraffin-embedded tissues.

  PMID 19012729 · PMC4506168 · Journal of cellular and molecular medicine · 2008 · 8 claims · 8 setups

  Full-text index only

  RCL2-fixed paraffin-embedded (RCL2P) tissue consistently gives the highest protein yield compared to FFPE and frozen tissue across extraction protocols

  normal rcl2p ffpe frozen yield 1-dimensional 2-dimensional

• Utilization of genomic signatures to identify phenotype-specific drugs.

  PMID 19714244 · PMC2729377 · PloS one · 2009 · 8 claims · 8 setups

  Full-text index only

  A RAS pathway gene expression signature applied to NCI-60 cells identifies compounds selectively active against RAS-activated cells, including the MEK inhibitor Hypothemycin

  nci-60 breast mda-mb-231 signature-drug gene signature